Share
Audrey Duval Derveloy
Sanofi has announced the appointment of Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs, and effective July 1, 2024. Audrey will also join Sanofi’s Executive Committee, reporting directly to CEO Paul Hudson, and will be based in Paris. In this role, she will manage Sanofi’s global stakeholder engagement, corporate social responsibility strategy, and oversee the company's Global Health Unit and philanthropic arm, Foundation S. Audrey will continue in her current position as President of Sanofi France.
Paul Hudson, CEO of Sanofi, expressed his enthusiasm for Audrey’s new role, noting her significant contributions to advancing the company’s modernization in France. “Audrey’s leadership has been vital in positioning Sanofi as a leading healthcare company in our home market. Her experience and business acumen make her well-suited to drive our global external engagement strategy and support our goal of becoming a science-driven company transforming medicine for patients worldwide,” said Hudson.
Audrey, who joined Sanofi from Novartis in September 2022, has a distinguished career in the healthcare industry. She began her career in public hospitals in Paris, moved on to research at the Pasteur Research Center in Hong Kong, and served as a Scientific Expert at Salusmed. Returning to France, Audrey worked at Pfizer in medical affairs before advancing through various roles at Novartis, including Business Franchise Head for Ophthalmology and Country President for Ireland.
In her new role, Audrey aims to build on Sanofi’s recent successes, including the launch of Beyfortus against RSV and the environmental transition of its industrial sites. “I am inspired by the dedication of our employees in France and look forward to leveraging these successes as we continue to modernize Sanofi and strengthen our position as an immunology leader,” said Audrey.
Related posts
.webp "Capstan Medical Appoints Marshall Mohr to Board of Directors")
